Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects With Acute Coronary Syndrome.

Next Previous
Trial Profile

A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects With Acute Coronary Syndrome.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Heparin; Low molecular weight heparins
  • Indications Acute coronary syndromes
  • Focus Therapeutic Use
  • Acronyms RADAR
  • Sponsors Regado Biosciences

Most Recent Events

  • 05 Dec 2012 A summary of the results of the RADAR study will be presented at the Oppenheimer 23rd Annual Healthcare Conference, according to a Regado Biosciences media release, as well as a summary of the results of the FDA end-of-phase 2 meeting.
  • 02 Aug 2012 Results published in the European Heart Journal.
  • 14 Mar 2012 Results will be presented at the BIO-Europe Spring 2012 conference.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top